GRANIX (tbo-filgrastim) Injection Teva announced that the FDA has approved Tbo-filgrastim (XM02 filgrastim injection solution), the first granulocyte colony-stimulating factor (G-CSF) to be approved ...
First New Treatment for Neutropenia Approved in the United States in 10 YearsMarks First Supportive Care Therapy for Cancer Patients from Teva Oncology JERUSALEM, Aug 30, 2012 -- Teva Pharmaceutical ...
Monkeys, after a prehabituation period, received total body irradiation (TBI) in Lucite ® restraining chairs. Approximately, 3–4 h after bone marrow harvest, the animals received TBI at a midline ...
The combination therapy is the first FDA approved for the mobilization of hematopoietic stem cells prior to autologous transplantation in patients with multiple myeloma. The FDA approved motixafortide ...
The US Food and Drug Administration (FDA) has expanded the indication for tbo-filgrastim (Granix, Teva), now allowing it to be self-administered by patients and their caregivers. Tbo-filgrastim, a ...
Gary Lyman, MD, MPH, an oncologist and hematologist, compares the uptake of filgrastim biosimlars with pegfilgrastim biosimilars. Gary Lyman, MD, MPH, is an oncologist, hematologist, and public health ...
The use of filgrastim vs pegfilgrastim in the auto-SCT population has been studied after high-dose melphalan in multiple myeloma patients. There were no differences in duration of grade 4 neutropenia ...
JERUSALEM — Teva Pharmaceutical today announced that the Food and Drug Administration has approved Granix (tbo-filgrastim) Injection for self-administration by patients and caregivers. With the ...
- APHEXDA is the first innovation in stem cell mobilization for multiple myeloma to be approved in the U.S. in a decade - - One dosage of APHEXDA plus filgrastim enabled a majority of patients to ...
Sandoz Filgrastim approved in all indications as the reference product Sandoz becomes first company to secure approval for two biosimilars in Japan Approval marks continued expansion of Sandoz' ...
The FDA has approved Aphexda plus filgrastim for the mobilization of hematopoietic stem cells in patients with multiple myeloma. The Food and Drug Administration (FDA) has approved Aphexda ...
Tbo-filgrastim is a solution for subcutaneous injection and will be supplied as a single use, preservative-free, prefilled syringe in doses of 300mcg/0.5mL and 480 mcg/0.8mL. Important Safety ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results